

# Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary

## Incidence

In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center-Hospital Hill and an additional 16 patients were seen for treatment of their recurrent or metastatic cancer after receiving initial treatment elsewhere. Five patients were diagnosed elsewhere and TMC-HH participated in work-up and/or staging studies but treatment was sought elsewhere. Figure 1 depicts the annual new accessions (cancers) since January 1, 2010. These numbers also include patients who had one or more primary cancers diagnosed in 2010 – 2014.

Figure 1





Figure 2 depicts the Class of Case. Class 00 cases were diagnosed at TMC-HH and went elsewhere for treatment. Class 13 was diagnosed and part of their first course treatment was done at TMC-HH; Class 14 was diagnosed and all first course treatment done at TMC-HH. Class 21 diagnosed elsewhere and came to TMC-HH for part of first course treatment; Class 22 was diagnosed elsewhere and came to TMC-HH for all of their first course treatment.

Figure 2



2014

The following table summarizes the primary sites by gender for 2014. The top five most frequent occurring cancers at Truman Medical Center in 2014 were: Breast, Lung, Colon, Prostate and Corpus Uteri. This is the fourth time in five years Corpus Uteri Cancer has been in the top five sites.

| <b>2014 Primary Sites</b>        | <b>Male</b> | <b>Female</b> | <b>Total #</b> | <b>Total %</b> |
|----------------------------------|-------------|---------------|----------------|----------------|
| <b>Oral Cavity &amp; Pharynx</b> | <b>8</b>    | <b>4</b>      | <b>12</b>      | <b>2.7</b>     |
| -Tongue                          | 1           | 0             | 1              | 0.2            |
| -Salivary Gland                  | 1           | 0             | 1              | 0.2            |
| -Gum & Other Mouth               | 1           | 2             | 3              | 0.7            |
| -Nasopharynx                     | 1           | 2             | 3              | 0.7            |
| -Tonsil                          | 3           | 0             | 3              | 0.7            |
| -Oropharynx                      | 1           | 0             | 1              | 0.2            |
| <b>Digestive System</b>          | <b>57</b>   | <b>35</b>     | <b>92</b>      | <b>20.4</b>    |
| -Esophagus                       | 6           | 2             | 8              | 1.8            |
| -Stomach                         | 4           | 3             | 7              | 1.5            |
| -Small Intestine                 | 2           | 2             | 4              | 0.9            |
| -Colon (Excluding Rectum)        | 15          | 13            | 28             | 6.2            |
| -Rectum & Rectosigmoid Junction  | 12          | 5             | 17             | 3.8            |
| -Anus, Anal Canal & Anorectum    | 1           | 3             | 4              | 0.9            |
| -Liver & Intrahepatic Bile Duct  | 6           | 1             | 7              | 1.5            |
| -Other Biliary                   | 0           | 1             | 1              | 0.2            |
| -Pancreas                        | 11          | 5             | 16             | 3.5            |
| <b>Respiratory System</b>        | <b>31</b>   | <b>33</b>     | <b>64</b>      | <b>14.2</b>    |
| -Nose, Nasal Cavity & Middle Ear | 0           | 1             | 1              | 0.2            |
| -Larynx                          | 4           | 3             | 7              | 1.5            |
| -Lung & Bronchus                 | 27          | 29            | 56             | 12.4           |
| <b>Bones &amp; Joints</b>        | <b>2</b>    | <b>0</b>      | <b>2</b>       | <b>0.4</b>     |
| -Bones & Joints                  | 2           | 0             | 2              | 0.4            |
| <b>Soft Tissue</b>               | <b>0</b>    | <b>2</b>      | <b>2</b>       | <b>0.4</b>     |
| -Soft Tissue (Including Heart)   | 0           | 2             | 2              | 0.4            |
| <b>Skin (Excluding BCC/SCC)</b>  | <b>7</b>    | <b>3</b>      | <b>10</b>      | <b>2.2</b>     |
| -Melanoma                        | 4           | 7             | 11             | 2.4            |
| <b>Breast</b>                    | <b>0</b>    | <b>88</b>     | <b>88</b>      | <b>19.5</b>    |
| -Breast                          | 0           | 88            | 88             | 19.5           |
| <b>Female Genital System</b>     | <b>0</b>    | <b>54</b>     | <b>54</b>      | <b>11.9</b>    |
| -Cervix Uteri                    | 0           | 17            | 17             | 4.4            |
| -Corpus & Uterus, NOS            | 0           | 20            | 20             | 2.4            |
| -Ovary                           | 0           | 9             | 9              | 2.0            |
| -Vagina                          | 0           | 2             | 2              | 0.4            |
| -Vulva                           | 0           | 6             | 6              | 1.3            |
| <b>Male Genital System</b>       | <b>32</b>   | <b>0</b>      | <b>32</b>      | <b>7.1</b>     |
| -Prostate                        | 27          | 0             | 27             | 6.0            |
| -Testis                          | 4           | 0             | 4              | 0.9            |
| -Other Male Genital Organs       | 1           | 0             | 1              | 0.2            |
| <b>Urinary System</b>            | <b>14</b>   | <b>14</b>     | <b>28</b>      | <b>6.2</b>     |
| -Urinary Bladder                 | 7           | 1             | 8              | 1.8            |

|                               |            |            |            |             |
|-------------------------------|------------|------------|------------|-------------|
| -Kidney & Renal Pelvis        | 6          | 11         | 17         | 3.8         |
| -Other Urinary Organs         | 1          | 2          | 3          | 0.4         |
| <b>Eye &amp; Orbit</b>        | <b>2</b>   | <b>0</b>   | <b>2</b>   | <b>0.4</b>  |
| -Eye & Orbit                  | 2          | 0          | 2          | 0.4         |
| <b>Brain &amp; Other CNS</b>  | <b>4</b>   | <b>7</b>   | <b>11</b>  | <b>2.4</b>  |
| -Brain                        | 4          | 4          | 8          | 1.8         |
| -Cranial Nervous System       | 0          | 3          | 3          | 0.7         |
| <b>Endocrine System</b>       | <b>5</b>   | <b>7</b>   | <b>12</b>  | <b>2.7</b>  |
| -Thyroid                      | 5          | 5          | 10         | 2.2         |
| -Other Endocrine incl Thymus  | 0          | 2          | 0          | 0.4         |
| <b>Lymphoma</b>               | <b>15</b>  | <b>3</b>   | <b>18</b>  | <b>4.0</b>  |
| -Hodgkin Lymphoma             | 1          | 1          | 2          | 0.4         |
| -Non-Hodgkin Lymphoma         | 14         | 2          | 16         | 3.5         |
| <b>Multiple Myeloma</b>       | <b>6</b>   | <b>1</b>   | <b>7</b>   | <b>1.5</b>  |
| -Multiple Myeloma             | 6          | 1          | 7          | 1.5         |
| <b>Leukemia</b>               | <b>8</b>   | <b>5</b>   | <b>13</b>  | <b>2.9</b>  |
| -Lymphocytic Leukemia         | 4          | 1          | 5          | 1.1         |
| -Myeloid & Monocytic Leukemia | 4          | 4          | 8          | 1.8         |
| <b>Kaposi Sarcoma</b>         | <b>2</b>   | <b>0</b>   | <b>2</b>   | <b>0.4</b>  |
| -Kaposi Sarcoma               | 2          | 0          | 2          | 0.4         |
| <b>Miscellaneous</b>          | <b>3</b>   | <b>1</b>   | <b>4</b>   | <b>0.9</b>  |
| -Miscellaneous                | 3          | 1          | 4          | 0.9         |
| <b>Totals</b>                 | <b>195</b> | <b>257</b> | <b>452</b> | <b>100%</b> |

## **Patient Demographics**

Data from the American Cancer Society: *Cancer Facts and Figures 2014* estimated that there would be 1,665,540 new cancer cases diagnosed in 2014 and of those, 33,890 will be diagnosed in Missouri. For 2015, The American Cancer Society estimated about 1,658,370 new cancer cases to be diagnosed. This estimate does not include carcinoma in situ (noninvasive cancer) of any site except urinary bladder, nor does it include basal cell or squamous cell skin. Missouri is estimated to have an increase by 34,680 new cancer cases.

2008-2012 Data from *SEER program & NCI State Cancer Profiles*, showed that Jackson County, MO ranked 74<sup>th</sup> in the state with a new cancer rate of 453.1 per 100,000 people. Jackson County however is 2<sup>nd</sup> in the state with reported cases of cancer with 3,240 and St Louis County had 5,880. The Missouri rate was 454.8 and the US rate was 453.3 per 100,000 based on data from 2008-2012.

Gender for Truman Medical Center's cancer patients was distributed as 44% males & 56% females.

Race distribution was 53% Caucasian; 35% Black; 1% Chinese; 3% Mexican; 1% Cuban; 2% Central/South American; 2% Spanish NOS and 3% Other.

Figure 3 represents new cases distributed by age at diagnosis. The highest percent of our patients were diagnosed between the age of 50 and 59 years old at 39%. The age range was 16 to 97 years with the average age being 55 years old.

Figure 3





Figure 4 represents County at diagnosis. 83% of TMC’s new patients were from Jackson Co, some patients were referred from other Missouri counties not surrounding the KC Metro area, and those were: Buchanan, Cass, Clay, Davies, Henry, Johnson, Platte and Stone. A few were referred from Kansas counties.

Figure 4



Truman Discount was the most common payer at diagnosis for patients at Truman Medical Center-Hospital Hill in 2014. Below is a table that breaks down the types of insurance coverage and the percentages. Most patients who are Self Pay & TMC discount often qualify for Medicaid after diagnosis.

| <b>Type of Insurance</b>   | <b>Total number of Patients</b> | <b>Percentage of Patients</b> |
|--|---------------------------------|-------------------------------|
| Self-Pay (TMC Discount)  | 111                             | 26                            |
| Self-Pay (No discount)   | 68                              | 16                            |
| Commercial Insurance (HMO/PPO)                                     | 60                              | 14                            |
| Insurance, Nos   | 1                               | 0                             |
| Medicaid   | 92                              | 21                            |
| Medicaid managed through Managed Health Plan (MC+)                 | 9                               | 2                             |
| Medicare only  | 32                              | 7                             |
| Medicare managed through Managed Health Plan (Commercial Medicare) | 23                              | 5                             |
| Medicare with Private Supplement                                   | 4                               | 1                             |
| Medicare with Medicaid Supplement                                  | 22                              | 5                             |
| TRICARE  | 1                               | 0                             |
| Veterans Affairs   | 1                               | 0                             |
| Public Health  | 0                               | 0                             |
| Unknown  | 1                               | 0                             |


### **Alcohol & Tobacco Usage**

Over 69% of all Truman newly diagnosed cancer patients reported current use of tobacco products (Cigarette, Cigar & Chew tobacco) at diagnosis or reported previous use. For the 56 newly diagnosed lung cancer patients, 79% used tobacco at diagnosis and 18% reported previous use.

For the 7 newly diagnosed liver cancer patients, 71% used alcohol at diagnosis and 29% reported previous use. Over 47% of all newly diagnosed patients reported current or past use of alcohol.

### **TNM Stage**

54% of all new patients had in-situ (non invasive) involvement of the primary tumor or invasive tumor confined to the primary organ. 16% of all new patients had distant metastasis at time of diagnosis. 9% of all new patients had a primary cancer that was not eligible for AJCC group staging, such as Brain/CNS, Bone Marrow & Unknown Primary, just to name a few. Some of the Class 00 cases seen at Truman Medical Center, fall into the “Unknown Stage” category as standard setters do not require Class 00 cases to be staged, but if stage is known, it is recorded.



**Top 5 sites by Best AJCC Stage \*\***

|                      | Stage 0 | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Unk. Stage/<br>NA |
|----------------------|---------|---------|---------|---------|---------|-------------------|
| Breast<br>N=88       | 71%     | 19%     | 24%     | 25%     | 5%      | 38%               |
| Lung<br>N=56         | 0%      | 5%      | 6%      | 17%     | 35%     | 13%               |
| Colon<br>N=28        | 6%      | 7%      | 3%      | 7%      | 9%      | 12%               |
| Prostate<br>N=27     | 0%      | 5%      | 18%     | 5%      | 13%     | 13%               |
| Corpus Uteri<br>N=20 | 0%      | 12%     | 0%      | 1%      | 3%      | 38%               |

### **Follow-up & Survival**

With a 1995 Reference Year, the registry followed 6,439 patients in 2014. The follow-up rate for all patients was 88% and the follow-up rate for the last five years has been above 90%.